OR WAIT null SECS
August 10, 2022
FDA has approved Coherus’ Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar for all five indications of Lucentis.
Sanofi and Innovent have entered into a strategic collaboration to accelerate development of oncology medicines and expand their presence in China.
Democrats approve curbs for Medicare plans, but not for commercial drug coverage.
August 09, 2022
Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).
The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer.
August 05, 2022
The OMNI Electric Utility Raceway power and data management system is designed to reduce risk and accelerate cleanroom delivery.
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
August 04, 2022
Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.
Better clinical data are needed, as well as strategies for tackling opioid abuse, tobacco use, and food safety.
August 03, 2022
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.